Navigation Links
The Leukemia & Lymphoma Society to Fund Research Focused on Long-Term and Late Effects of Cancer Treatment
Date:9/14/2009

WHITE PLAINS, N.Y., Sept. 14 /PRNewswire/ -- The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life.

While research continues to seek new safe and effective drugs, what patients need now is for current therapies to be made less harmful without sacrificing their effectiveness.

In a new initiative, The Leukemia & Lymphoma Society (LLS) will invest in research designed to discover the biological mechanisms that cause late effects, and to develop and test measures to prevent or at least significantly reduce toxicities. LLS is seeking requests for proposals from scientists studying these issues. ( http://www.leukemia-lymphoma.org/graphics/National/QualityofLifeResearchFundingOpportunity.pdf)

The pediatric cancer story has shown us that the goal is achievable. Years of research and clinical trials enabled survival rates to reach nearly 90% for children with acute lymphocytic leukemia. But then the medical and research community recognized that the serious late effects were severely impacting quality of life. High-dose radiation treatments, once thought critical to cures, have been eliminated for most children, significantly reducing cognitive deficits and other once common side-effects.

Now LLS has set a goal of doing for all cancer patients, regardless of age, what has been achieved for many children -- survival with good quality of life.

The initiative is being led by Anna T. Meadows, M.D., medical director of the Cancer Survivorship and Living Well After Cancer Program at the Children's Hospital of Philadelphia. Dr. Meadows is an internationally recognized pioneer in late effects research; she helped quantify the serious consequences of high-dose radiation and eliminate it from curative treatments for most children with leukemia and lymphoma.

"We must find the answers and test them as soon as possible," says Dr. Meadows. "We must be determined and courageous -- funders, researchers, and patients alike -- because survival is just the first part of the struggle to cure cancer; the quality of that survival matters."

To learn more about the LLS Quality of Life Funding Initiative, visit http://www.leukemia-lymphoma.org/graphics/National/QualityofLifeResearchFundingOpportunity.pdf

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

    Contact: Andrea Greif
    (914) 821-8958
    andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
6. Mutant Genes in High-Risk Childhood Leukemias Identified
7. Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
8. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
9. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):